医学
贝伐单抗
伤口愈合
瘀斑
伤口裂开
外科
不利影响
手术伤口
血管内皮生长因子
血管生成
裂开
乳腺癌
癌症
化疗
内科学
血管内皮生长因子受体
作者
Chad R. Gordon,Yuri Rojavin,Mitul Patel,James E. Zins,Generosa Grana,Brian R. Kann,Robert L. Simons,Umar Atabek
出处
期刊:Annals of Plastic Surgery
[Ovid Technologies (Wolters Kluwer)]
日期:2009-06-01
卷期号:62 (6): 707-709
被引量:140
标识
DOI:10.1097/sap.0b013e3181828141
摘要
Bevacizumab (Avastin, Genentech, Inc, San Francisco, CA), a humanized monoclonal antibody against vascular endothelial growth factor, was recently approved for the treatment of metastatic breast cancer.A PubMed and OVID search was performed using keywords: bevacizumab, Avastin, wound healing, VEGF, angiogenesis, and colorectal cancer. Our objective was to review the current literature in regard to bevacizumab and its adverse effects on surgical wound healing.Bevacizumab has been associated with multiple complications in regard to wound healing, such as dehiscence, ecchymosis, surgical site bleeding, and wound infection. Current literature suggests patients should wait at least 6 to 8 weeks (>40 days) after cessation to have surgery (half-life = 20 days). In addition, postoperative reinitiation of bevacizumab must wait > or =28 days to prevent an increased risk of wound healing complications, and the surgical incision should be fully healed.The adverse effects of bevacizumab in regard to wound healing must be considered in all surgical patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI